TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter
Cancer Res
.
2017 Jun 15;77(12):3376-3378.
doi: 10.1158/0008-5472.CAN-17-0412.
Epub 2017 Jun 5.
Authors
Anna H Turaj
1
,
Lekh N Dahal
1
,
Stephen A Beers
1
,
Mark S Cragg
1
,
Sean H Lim
2
Affiliations
1
Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
2
Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. s.h.lim@soton.ac.uk.
PMID:
28584185
DOI:
10.1158/0008-5472.CAN-17-0412
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Humans
Receptor, ErbB-2
Toll-Like Receptors*
Trastuzumab*
Substances
Toll-Like Receptors
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab
Grants and funding
15269/CRUK_/Cancer Research UK/United Kingdom
20537/CRUK_/Cancer Research UK/United Kingdom
C30010/A15269/CRUK_/Cancer Research UK/United Kingdom